Literature DB >> 32078355

Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017-2018.

Lara Carson Weinstein1, Qais Iqbal1, Amy Cunningham1, Robin Debates1, Greg Landistratis1, Patrick Doggett1, Alexis Silverio1.   

Abstract

Objectives. To describe and report initial outcomes of a low-threshold, group-based primary care medication for opioid use disorder (OUD) program in a federally qualified health center.Methods. We performed a retrospective chart review of patients enrolled in the program from October 4, 2017, to October 3, 2018, in Philadelphia, Pennsylvania. The main outcome measure was time retained in treatment, defined as time from treatment initiation to unplanned treatment termination. Secondary outcomes were the relationships between treatment retention and cocaine use or housing status. We analyzed retention in treatment using Kaplan-Meier survival estimates.Results. The 3- and 6-month retention rates were 82% and 63%, respectively. The log-rank test showed no significant differences for comparisons between homeless versus not homeless (P = .25) and cocaine use versus no cocaine use (P = .12).Conclusions. The medication for OUD program engaged a large number of patients from marginalized groups. Three- and 6-month retention rates were comparable with those reported of other federally qualified health center populations.Public Health Implications. Integrating treatment of OUD into primary care shows promise for increasing access to and retention in medication for OUD services. The federally qualified health center payment structure supports the sustainability of the group visit model.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32078355      PMCID: PMC7067078          DOI: 10.2105/AJPH.2019.305525

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  19 in total

1.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

2.  Cocaine use and buprenorphine compliance.

Authors:  Peter A DeMaria
Journal:  J Addict Med       Date:  2015 May-Jun       Impact factor: 3.702

3.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Authors:  Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

4.  Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic.

Authors:  Sara L Doorley; Cheryl J Ho; Elizabeth Echeverria; Charles Preston; Huy Ngo; Ahmad Kamal; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2016-11-29       Impact factor: 3.716

5.  Group medication management for buprenorphine/naloxone in opioid-dependent veterans.

Authors:  Reisel Berger; Carmen Pulido; Jonathan Lacro; Stephen Groban; Shannon Robinson
Journal:  J Addict Med       Date:  2014 Nov-Dec       Impact factor: 3.702

6.  Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.

Authors:  Sharon Stancliff; Herman Joseph; Chunki Fong; Terry Furst; Sandra D Comer; Perrine Roux
Journal:  J Addict Dis       Date:  2012

7.  Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.

Authors:  Chinazo O Cunningham; Angela Giovanniello; Hillary V Kunins; Robert J Roose; Aaron D Fox; Nancy L Sohler
Journal:  Am J Addict       Date:  2013 Jul-Aug

8.  A meta-analysis of retention in methadone maintenance by dose and dosing strategy.

Authors:  Yan-Ping Bao; Zhi-Min Liu; David H Epstein; Cun Du; Jie Shi; Lin Lu
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

9.  Treating homeless opioid dependent patients with buprenorphine in an office-based setting.

Authors:  Daniel P Alford; Colleen T LaBelle; Jessica M Richardson; James J O'Connell; Carole A Hohl; Debbie M Cheng; Jeffrey H Samet
Journal:  J Gen Intern Med       Date:  2007-02       Impact factor: 5.128

10.  Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.

Authors:  Jamie Carter; Barry Zevin; Paula J Lum
Journal:  Addict Sci Clin Pract       Date:  2019-05-06
View more
  5 in total

1.  Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs.

Authors:  Elisabeth Poorman; Sara N Glick; Jonathan K D Hiser; Elenore Bhatraju; Judith I Tsui
Journal:  J Subst Abuse Treat       Date:  2021-03-19

2.  Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program.

Authors:  Kathleen M Ward; Ayden Scheim; Jonathan Wang; Benjamin Cocchiaro; Katie Singley; Alexis M Roth
Journal:  Drug Alcohol Depend Rep       Date:  2022-04-26

3.  A Qualitative Exploration of the Functional, Social, and Emotional Impacts of the COVID-19 Pandemic on People Who Use Drugs.

Authors:  Erin L Kelly; Megan K Reed; Kathryn M Schoenauer; Kelsey Smith; Kristina Scalia-Jackson; Sequoia Kay Hill; Erica Li; Lara Weinstein
Journal:  Int J Environ Res Public Health       Date:  2022-08-08       Impact factor: 4.614

4.  Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.

Authors:  Lauren Peterson; Manoradhan Murugesan; Robert Nocon; Hank Hoang; Joshua Bolton; Neda Laiteerapong; Harold Pollack; Jeanne Marsh
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

5.  Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder.

Authors:  Kristi Lynn Stringer; Kirsten J Langdon; Michelle McKenzie; Brad Brockmann; Phillip Marotta
Journal:  J Subst Abuse Treat       Date:  2020-12-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.